子宫内膜异位症患者整倍体胚胎移植前延长口服GnRH拮抗剂给药:一项前瞻性随机初步非劣效性试验
该前瞻性随机非劣效性初步试验将30例子宫内膜异位症不孕患者随机分为口服艾拉戈克200mg每日两次共56天组(n=15)与肌注亮丙瑞林微球3.75mg每28天组(n=15),两组移植前最大内膜厚度、阳性妊娠试验率及活产率均无显著差异。
要点
- 口服艾拉戈克组与肌注亮丙瑞林组移植前最大内膜厚度分别为10.9±2.8mm与10.3±2.0mm(P=0.54)。
- 阳性妊娠试验率口服组86.7% vs 肌注组93.3%(P=0.54),活产率87% vs 80%(P=0.62)。
- 作者认为口服GnRH拮抗剂2个月方案可获得与胃肠外GnRH激动剂等效的鼓励性结局。
核心结论
- 子宫内膜异位症患者整倍体胚胎移植前口服适当剂量艾拉戈克2个月可获得与胃肠外GnRH激动剂等效的高度鼓励性结局,可能成为这些患者更倾向的选择。
研究设计与样本
- 前瞻性随机非劣效性初步试验,纳入手术确诊子宫内膜异位症的不孕患者30例,随机分为口服艾拉戈克200mg每日两次共56天组(组1,n=15)与肌注醋酸亮丙瑞林缓释制剂3.75每28天组(组2,n=15)。
主要发现
- 两组基线特征无差异。
- 移植前最大子宫内膜厚度组1为10.9±2.8mm vs 组2为10.3±2.0mm(P=0.54)。
- 组2第5天整倍体囊胚移植比例有升高趋势(53% vs 80%),但未报告统计学检验。
- 阳性妊娠试验率组1为86.7% vs 组2为93.3%(P=0.54),活产率组1为87% vs 组2为80%(P=0.62),均无差异。
局限性
- 原文报告为初步试验(pilot trial),样本量为30例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Is oral administration of a gonadotrophin releasing hormone (GnRH) antagonist for 2 months before euploid embryo transfer in patients with endometriosis non-inferior to intramuscular administration of a long-acting GnRH agonist for a similar period? DESIGN: Prospective randomized non-inferiority pilot trial of infertility patients with surgically diagnosed endometriosis. Thirty patients were randomized to receive either oral elagolix 200 mg twice daily for 56 days (group 1; n = 15) or an intramuscular depot preparation of leuprolide acetate 3.75 every 28 days (group 2; n = 15) before euploid embryo transfer. RESULTS: No differences were found in baseline characteristics between the two groups. Nor were any differences found between the two groups in maximal endometrial thickness before embryo transfer (10.9 ± 2.8 mm versus 10.3 ± 2.0 mm; P = 0.54). Despite a trend towards transfer of a higher percentage of day-5 euploid blastocysts in group 2 (53% versus 80%), no differences were found in positive pregnancy tests (86.7% versus 93.3%; P = 0.54) or live birth rates between the groups (87% versus 80%; P = 0.62). CONCLUSION: Administration of the oral GnRH antagonist elagolix in appropriate doses for 2 months in women with endometriosis before euploid embryo transfer yields highly encouraging outcomes that are equivalent to those achieved with parenteral administration of a GnRH agonist, which could make this a more desired approach in these patients.
引用
- Surrey ES, Katz-Jaffe M, Kondapalli LA, et al. Prolonged oral GnRH-antagonist administration before euploid embryo transfer in patients with endometriosis: a prospective randomized pilot non-inferiority trial. Reprod Biomed Online. 2025. PMID: 41092830. doi:10.1016/j.rbmo.2025.105125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。